Quotient Sciences Translational Pharmaceuticals Quotient Sciences Translational Pharmaceuticals

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Chiesi Group","pharmaFlowCategory":"D","amount":"$425.0 million","upfrontCash":"$25.0 million","newsHeadline":"Moderna and Chiesi Group Establish Collaboration to Discover and Develop mRNA Therapeutics for Pulmonary Arterial Hypertension (PAH)","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"September 2020","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Moderna Therapeutics"},{"orgOrder":0,"company":"Recursion Pharma","sponsor":"Bayer AG","pharmaFlowCategory":"D","amount":"$1,030.0 million","upfrontCash":"$30.0 million","newsHeadline":"Bayer Collaborates with Recursion to Strengthen Digital Drug Discovery and Advance New Therapies for Fibrotic Diseases","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"September 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Recursion Pharma"},{"orgOrder":0,"company":"Rubedo Life Sciences","sponsor":"California Institute for Regenerative Medicine","pharmaFlowCategory":"D","amount":"$1.4 million","upfrontCash":"Undisclosed","newsHeadline":"Rubedo Life Sciences Awarded $1.45M in Funding From the California Institute for Regenerative Medicine (CIRM) for Idiopathic Pulmonary Fibrosis Program","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Rubedo Life Sciences"},{"orgOrder":0,"company":"Affibody","sponsor":"Chiesi Group","pharmaFlowCategory":"D","amount":"$214.0 million","upfrontCash":"Undisclosed","newsHeadline":"Affibody And Chiesi Group Collaborate To Develop And Commercialize Innovative Treatments For Respiratory Diseases","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Discovery","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Affibody"},{"orgOrder":0,"company":"AGC Biologics","sponsor":"The Jikei University","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AGC Biologics Signs Exosome Agreement with The Jikei University in Japan for Idiopathic Pulmonary Fibrosis (IPF) Project","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2023","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"AGC Biologics"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Loading...

    All Data

    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Product Type
            filter News Type

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Product Type

              Companies

              AGC Biologics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              AGC Biologics Signs Exosome Agreement with The Jikei University in Japan for Idiopathic Pulmonary Fibrosis (IPF) Project

              Details:

              Under the agreement, AGC Biologics will assume a technology transfer and feasibility study for a drug product focused on the treatment of Idiopathic pulmonary fibrosis at the CDMO's center of Cell and Gene Excellence in Milan.

              Lead Product(s): Undisclosed

              Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed

              Highest Development Status: Discovery Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: The Jikei University

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement April 03, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Affibody

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Sweden
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Affibody And Chiesi Group Collaborate To Develop And Commercialize Innovative Treatments For Respiratory Diseases

              Details:

              Under the terms of the collaboration, Affibody and Chiesi Group will collaborate closely to progress up to three programs based on Affibody® molecules against undisclosed targets for respiratory diseases.

              Lead Product(s): Undisclosed

              Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed

              Highest Development Status: Discovery Product Type: Large molecule

              Partner/Sponsor/Collaborator: Chiesi Group

              Deal Size: $214.0 million Upfront Cash: Undisclosed

              Deal Type: Collaboration March 07, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Rubedo Life Sciences

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Rubedo Life Sciences Awarded $1.45M in Funding From the California Institute for Regenerative Medicine (CIRM) for Idiopathic Pulmonary Fibrosis Program

              Details:

              The funding will support research and development of a pharmacological regenerative treatment of idiopathic pulmonary fibrosis (IPF), RBO-0618, targeting senescent lung stem cells.

              Lead Product(s): RBO-0618

              Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: RBO-0618

              Highest Development Status: Discovery Product Type: Small molecule

              Partner/Sponsor/Collaborator: California Institute for Regenerative Medicine

              Deal Size: $1.4 million Upfront Cash: Undisclosed

              Deal Type: Funding February 06, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Moderna Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Moderna and Chiesi Group Establish Collaboration to Discover and Develop mRNA Therapeutics for Pulmonary Arterial Hypertension (PAH)

              Details:

              Under the terms of the agreement, Moderna will lead discovery efforts, leveraging its leading mRNA technology and delivery platforms along with Chiesi’s expertise in the field of PAH biology.

              Lead Product(s): mRNA Therapeutics

              Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed

              Highest Development Status: Discovery Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Chiesi Group

              Deal Size: $425.0 million Upfront Cash: $25.0 million

              Deal Type: Collaboration September 16, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Recursion Pharma

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Bayer Collaborates with Recursion to Strengthen Digital Drug Discovery and Advance New Therapies for Fibrotic Diseases

              Details:

              The partnership will leverage Recursion’s purpose-built-AI-guided drug discovery platform and Bayer’s small molecule compound library and deep scientific expertise to discover and develop new treatments for fibrotic diseases of the lung, kidney, heart and more.

              Lead Product(s): Undisclosed

              Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed

              Highest Development Status: Discovery Product Type: Small molecule

              Partner/Sponsor/Collaborator: Bayer AG

              Deal Size: $1,030.0 million Upfront Cash: $30.0 million

              Deal Type: Collaboration September 09, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Douglas Pharma, a New Zealand success story, with CDMO capabilities for softgels, liquids, tablets, capsules & powders.
              Post Enquiry
              POST ENQUIRY